Perspective Therapeutics (NYSEAMERICAN:CATX) Posts Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) issued its quarterly earnings data on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04, FiscalAI reports. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX traded up $0.12 during midday trading on Monday, reaching $3.88. 1,134,087 shares of the company were exchanged, compared to its average volume of 2,837,002. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16. The stock has a fifty day simple moving average of $4.56 and a 200 day simple moving average of $3.58.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. B. Riley Financial raised their price objective on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a report on Tuesday, March 17th. Piper Sandler assumed coverage on Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. Royal Bank Of Canada dropped their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, March 17th. Finally, UBS Group raised their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.63.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its holdings in Perspective Therapeutics by 36.5% in the 4th quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock valued at $227,000 after purchasing an additional 22,074 shares in the last quarter. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $31,000. Opaleye Management Inc. purchased a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $3,257,000. Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $35,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Perspective Therapeutics in the 4th quarter valued at approximately $262,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.